Can We Slow Neurodegeneration in Multiple Indications without Reducing Neurofilament Light Chain?
Time: 2:00 pm
day: Conference Day 2
Details:
- Reviewing data on NFL in different neurodegenerative diseases
- Exploring examples of different therapeutic trials where NFL was reduced with treatment response
- Determining if there are neurodegenerative patient populations for which NFL is not a relevant marker of disease
- Evaluating feasibility for controlling baseline heterogeneity with NFL for more confident confirmation of efficacy
- If NFL is not a ubiquitous marker of disease progression, what other biomarkers in other pathways should be considered?
